Hosted on MSN7d
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics ...
Capricor Completes Submission Of BLA For Deramiocel For Treatment Of Duchenne Muscular Dystrophy
"The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. This BLA is the culmination of a body of work that has been focused on bringing this potentially ...
The Pharma Letter8d
Capricor completes BLA submission for deramiocel
US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) ...
Hosted on MSN15d
Savara Begins FDA Submission for Rare Lung Disease Treatment
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential ...
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology firm specializing in innovative cell and exosome-based therapies for rare diseases, finalized the submission of its Biologics License ...